Published in Cancer on November 01, 1972
Detection of occult bone marrow micrometastases in patients with operable lung carcinoma. Ann Surg (1995) 1.13
Oat cell carcinoma mimicking acute leukemia. West J Med (1978) 0.75
Chemotherapy for carcinoma of the bronchus--a brief review. Postgrad Med J (1973) 0.75
Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med (1979) 6.00
Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol (1995) 2.26
Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer (1993) 2.15
No evidence of acute cardiovascular complications of chemotherapy for testicular cancer: an analysis of the Testicular Cancer Intergroup Study. J Clin Oncol (1992) 2.11
Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep (1980) 1.99
Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol (1988) 1.84
Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol (1994) 1.79
Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol (1995) 1.77
Pleural mesothelioma: clinical features and therapeutic implications. Ann Intern Med (1977) 1.70
Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease. J Intern Med (1995) 1.66
Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann Oncol (2003) 1.63
Clinical studies with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (NSC 79037). Cancer Res (1971) 1.57
Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res (1994) 1.55
The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol (1989) 1.53
Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. J Clin Oncol (2005) 1.50
Hormonal therapy of breast cancer: new approaches and concepts. Ann Intern Med (1978) 1.48
Staging relationships and outcome in early stage testicular cancer: a report from the Testicular Cancer Intergroup Study. J Urol (1991) 1.47
Prognostic impact of histologic demonstration of chromogranin A and neuron specific enolase in pulmonary adenocarcinoma. Ann Oncol (1991) 1.47
Treatment of breast cancer with medroxyprogesterone acetate. Ann Intern Med (1968) 1.45
Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med (1977) 1.42
Severe neurotoxicity from vinorelbine-paclitaxel combinations. J Natl Cancer Inst (1996) 1.40
Cis-diamminedichloroplatinum (II). A new anticancer drug. Ann Intern Med (1977) 1.40
Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years--an analysis of 1,714 consecutive patients. J Clin Oncol (1995) 1.39
[Small cell lung cancer]. Ugeskr Laeger (1996) 1.39
Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst (1998) 1.32
Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep (1972) 1.32
Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med (1987) 1.30
A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis. Ann Oncol (2006) 1.29
Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res (1994) 1.28
Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinician. J Natl Cancer Inst (1990) 1.22
Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial. Eur J Cancer (1994) 1.22
Silent pulmonary embolism in patients with deep venous thrombosis. Incidence and fate in a randomized, controlled trial of anticoagulation versus no anticoagulation. J Intern Med (1994) 1.20
Mortality and morbidity in long-term surviving patients treated with chemotherapy with or without irradiation for small-cell lung cancer. J Clin Oncol (1986) 1.19
Bone-marrow examination in 100 consecutive patients with bronchogenic carcinoma. Lancet (1971) 1.18
Cytotoxic drug-induced pulmonary disease: update 1980. Am J Med (1980) 1.18
Treatment of small-cell carcinoma of the lung monitored by sequential flow cytometric DNA analysis. Cancer Res (1982) 1.18
The prognostic influence of serum neuron specific enolase in small cell lung cancer. Br J Cancer (1988) 1.18
Lung cancer: diagnosis in metastatic sites. Semin Oncol (1974) 1.17
Scanning and radiology of the carpal scaphoid bone. Acta Orthop Scand (1979) 1.16
Methodology for the assessment of new dichotomous diagnostic tests. J Chronic Dis (1981) 1.16
Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies. Cancer Res (1993) 1.15
Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy. Lancet (1987) 1.15
Phase I study of (6R)-5,10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis. J Natl Cancer Inst (1993) 1.15
N-Acylethanolamines and precursor phospholipids - relation to cell injury. Chem Phys Lipids (2000) 1.15
Efficacy of 6-diazo-5-oxo-L-norleucine and N-[N-gamma-glutamyl-6-diazo-5-oxo-norleucinyl]-6-diazo-5-oxo-norleucine against experimental tumors in conventional and nude mice. Cancer Res (1979) 1.14
Hormonal polypeptides and amine metabolites in small cell carcinoma of the lung, with special reference to stage and subtypes. Cancer (1980) 1.12
Camptothecins: a review of their development and schedules of administration. Eur J Cancer (1998) 1.12
Lysozymuria and renal tubular dysfunction in monocytic and myelomonocytic leukemia. Am J Med (1969) 1.11
Lung cancer. Cancer Chemother Biol Response Modif (1991) 1.11
Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: experimental and clinical studies. J Liposome Res (2003) 1.11
Hypercalcemia associated with neoplastic disease. Ann Intern Med (1970) 1.10
Neuron specific enolase, carcinoembryonic antigen and lactate dehydrogenase as indicators of disease activity in small cell lung cancer. Eur J Cancer Clin Oncol (1989) 1.10
5-Azacytidine. A new anticancer drug with effectiveness in acute myelogenous leukemia. Ann Intern Med (1976) 1.10
Doxorubicin-polymer conjugates: further demonstration of the concept of enhanced permeability and retention. Clin Cancer Res (1999) 1.09
Magnesium depletion enhances cisplatin-induced nephrotoxicity. Cancer Chemother Pharmacol (2005) 1.08
Progressive paresthesias after cessation of therapy with very high-dose cisplatin. Cancer Chemother Pharmacol (1989) 1.08
Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry. Carcinogenesis (1991) 1.08
Challenges posed by non-random missing quality of life data in an advanced-stage colorectal cancer clinical trial. Psychooncology (2000) 1.08
Role of chemotherapy in head and neck cancer: systemic use of single agents and combinations in advanced disease. Head Neck Surg (1980) 1.08
Non-small-cell lung cancer--stalemate or progress? N Engl J Med (2000) 1.08
Commentary: current status of chemotherapy for non-small cell lung cancer. Cancer Treat Rep (1982) 1.08
Current results of the screening program at the Division of Cancer Treatment, National Cancer Institute. Eur J Cancer (1981) 1.07
Proceedings: Frequency, diagnosis, and treatment of brain metastases in 247 consecutive patients with bronchogenic carcinoma. Cancer (1974) 1.06
Anticoagulant therapy in deep venous thrombosis. A randomized controlled study. Thromb Res (1994) 1.06
Chemotherapy versus chemotherapy plus irradiation in limited small cell lung cancer. Results of a controlled trial with 5 years follow-up. Br J Cancer (1986) 1.05
Clonal heterogeneity of small-cell anaplastic carcinoma of the lung demonstrated by flow-cytometric DNA analysis. Cancer Res (1980) 1.05
Combination chemotherapy of advanced lung cancer: a randomized trial. Cancer (1976) 1.05
Metastatic patterns in small-cell lung cancer: correlation of autopsy findings with clinical parameters in 537 patients. J Clin Oncol (1987) 1.05
Multiple endocrine adenomatosis of mixed type. Acta Med Scand (1976) 1.02
Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastine. J Clin Oncol (1984) 1.02
Adjuvant chemotherapy in lung cancer: review and prospects. Cancer (1977) 1.02
Clinical and preclinical activity of 2',2'-difluorodeoxycytidine (gemcitabine). Cancer Treat Rev (1993) 1.02
Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin: analysis of toxicities and predictors of outcome. Cancer (2001) 1.01
The variability of individual tolerance to methotrexate in cancer patients. Br J Cancer (1971) 1.01
Pulmonary toxicity of antitumor agents. Cancer Treat Rev (1983) 1.00
Long-term disease-free survival in small-cell carcinoma of the lung: a study of clinical determinants. J Clin Oncol (1986) 1.00
Acute nonlymphocytic leukemia, preleukemia, and solid tumors following intensive chemotherapy of small cell carcinoma of the lung. Blood (1985) 0.99
Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast. Am J Med (1985) 0.99
Continuous versus alternating combination chemotherapy for advanced small cell carcinoma of the lung. Cancer Res (1983) 0.98
Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma. Cancer Treat Rep (1985) 0.97
Superiority of cisplatin or carboplatin in combination with teniposide and vincristine in the induction chemotherapy of small-cell lung cancer. A randomized trial with 5 years follow up. Ann Oncol (1996) 0.97
Chemotherapy in malignant mesothelioma: a review. Cancer Chemother Pharmacol (1991) 0.96
Bone marrow involvement in small cell anaplastic carcinoma of the lung: prognostic and therapeutic aspects. Cancer (1980) 0.95
Long-term survivors with small cell carcinoma of the lung. Eur J Cancer (1980) 0.95
The clinical and screening age-at-onset distribution for the MEN-2 syndrome. Am J Hum Genet (1989) 0.95
Cell kinetic studies in patients with small cell carcinoma of the lung. Cancer (1974) 0.94
Formation of N-acyl-phosphatidylethanolamines and N-acetylethanolamines: proposed role in neurotoxicity. Biochem Pharmacol (1998) 0.94
Testicular carcinoma in Denmark 1976-1980. Stage and selected clinical parameters at presentation. Acta Radiol Oncol (1984) 0.94
The rediscovery of DON (6-diazo-5-oxo-L-norleucine). Recent Results Cancer Res (1980) 0.94
Chemotherapy of advanced small-cell anaplastic carcinoma. Superiority of a four-drug combination to a three-drug combination. Ann Intern Med (1978) 0.93
The chemotherapy of Hodgkin's disease: past experiences and future directions. Cancer (1978) 0.93